<DOC>
	<DOCNO>NCT02637687</DOCNO>
	<brief_summary>This multicenter , open label , Phase 1/2 study pediatric patient advance solid primary CNS tumor . LOXO‑101 ( larotrectinib ) administer orally ( PO ) twice daily ( BID ) , dose adjust body surface area ( BSA ) .</brief_summary>
	<brief_title>Oral TRK Inhibitor LOXO-101 ( Larotrectinib ) Treatment Advanced Pediatric Solid Primary Central Nervous System Tumors</brief_title>
	<detailed_description>This multicenter , open label , Phase 1/2 study pediatric patient advance solid primary CNS tumor . LOXO‑101 ( larotrectinib ) administer orally ( PO ) twice daily ( BID ) , dose adjust body surface area ( BSA ) . Dose Escalation Phase proceed plan 4 dose level , MTD reach , Sponsor determine suitable dose achieve base PK exposure.. Expansion Cohorts may enrol good characterize safety efficacy patient specific abnormality NTRK gene protein .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>Pediatric patient ≥ 1 year old Cycle 1 Day 1 ( C1D1 ) Phase 1 : Between 1 21 year age C1D1 locally advance metastatic solid tumor primary CNS tumor relapse , progress nonresponsive available therapy standard available systemic curative therapy , ≥1 month old diagnosis malignancy document NTRK fusion progress nonresponsive available therapy , standard available curative therapy exist patient locally advance infantile fibrosarcoma would require , opinion Investigator , disfigure surgery limb amputation achieve complete surgical resection Phase 2 : Ages &gt; /= 1 month age C1D1 locally advance metastatic infantile fibrosarcoma , Patients locally advance infantile fibrosarcoma would require , opinion Investigator , disfigure surgery limb amputation achieve complete surgical resection enrollment age 1 month 21 year age C1D1 locally advance metastatic solid tumor primary CNS tumor relapse , progress nonresponsive available therapy standard available systemic curative therapy document NTRK gene fusion ( identify molecular assay routinely perform CLIA similarlycertified laboratory ) ( include Expansion Phase ) potential patient older 21 year age tumor diagnosis histology typical pediatric patient NTRK fusion may consider enrollment follow discussion local site Investigator Sponsor 's Medical Monitor . Karnofsky ( 16 year old old ) Lansky ( young 16 year ) performance score least 50 Adequate hematologic function : Absolute neutrophil count ( ANC ) ≥ 1.0 109/L , platelet count ≥ 100.0 109/L hemoglobin ≥ 8.0 g/dL ( patient bone marrow involvement evaluable hematologic DLT enroll ANC ≥ 0.75 109/L , platelet count ≥ 50.0 109/L hemoglobin ≥ 8.0 g/dL ) Adequate hepatic function : Bilirubin ( sum conjugate + unconjugated ) ≤ 1.5 upper limit normal ( ULN ) age ( patient document Gilbert 's Disease may enrol Sponsor approval ) . Adequate renal function : Estimated glomerular filtration rate ≥ 30 mL/minute use CockroftGault formula : serum creatinine base age/gender outline protocol Investigational agent , anticancer therapy , major surgery within 14 day ( 2 week ) prior C1D1 Clinically significant active cardiovascular disease history prolong QT interval correct heart rate ( QTc ) Current treatment strong cytochrome P450 ( CYP ) 3A4 inhibitor inducer ( EIAEDs dexamethasone CNS tumor metastasis , stable dose , allow ) Phase 2 Only : Prior progression receive approve investigational tyrosine kinase inhibitor target TRK , include entrectinib , crizotinib lestaurtanib . Patients receive TRK inhibitor le 28 day treatment discontinue intolerance remain eligible .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>NTRK1</keyword>
	<keyword>NTRK2</keyword>
	<keyword>NTRK3</keyword>
	<keyword>Fusion</keyword>
	<keyword>Tumors</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>CNS Tumors</keyword>
	<keyword>Central Nervous System Tumors</keyword>
	<keyword>NTRK Fusion Positive</keyword>
	<keyword>TRKA</keyword>
	<keyword>TRKB</keyword>
	<keyword>TRKC</keyword>
	<keyword>Infantile Fibrosarcoma</keyword>
	<keyword>NTRK Gene Rearrangements</keyword>
	<keyword>TRK Fusion</keyword>
	<keyword>NTRK1 fusion</keyword>
	<keyword>NTRK2 fusion</keyword>
	<keyword>NTRK3 fusion</keyword>
	<keyword>NTRK1 gene rearrangement</keyword>
	<keyword>NTRK2 gene rearrangement</keyword>
	<keyword>NTRK3 gene rearrangement</keyword>
	<keyword>ETV6-NTRK3</keyword>
	<keyword>ETV6</keyword>
	<keyword>ETV6 fusion</keyword>
	<keyword>ETV6 gene rearrangement</keyword>
	<keyword>Solid CNS tumor</keyword>
	<keyword>Primary CNS tumor</keyword>
	<keyword>Advanced CNS tumor</keyword>
	<keyword>Metastatic CNS tumor</keyword>
	<keyword>Metastatic infantile fibrosarcoma</keyword>
	<keyword>Advanced infantile fibrosarcoma</keyword>
	<keyword>Fibrosarcoma</keyword>
	<keyword>Congenital mesoblastic nephroma</keyword>
	<keyword>Congenital nephroma</keyword>
	<keyword>Thyroid</keyword>
	<keyword>Larotrectinib</keyword>
</DOC>